InnoCare Financial Statements From 2010 to 2025
| INCPF Stock | USD 2.05 0.08 3.76% |
Check InnoCare Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among InnoCare Pharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . InnoCare financial statements analysis is a perfect complement when working with InnoCare Pharma Valuation or Volatility modules.
InnoCare |
InnoCare Pharma Limited Company Profit Margin Analysis
InnoCare Pharma's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current InnoCare Pharma Profit Margin | (1.96) % |
Most of InnoCare Pharma's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, InnoCare Pharma Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, InnoCare Pharma Limited has a Profit Margin of -1.9606%. This is 82.51% lower than that of the Healthcare sector and 91.49% lower than that of the Biotechnology industry. The profit margin for all United States stocks is 54.38% higher than that of the company.
InnoCare Pharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining InnoCare Pharma's current stock value. Our valuation model uses many indicators to compare InnoCare Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across InnoCare Pharma competition to find correlations between indicators driving InnoCare Pharma's intrinsic value. More Info.InnoCare Pharma Limited is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the InnoCare Pharma's earnings, one of the primary drivers of an investment's value.About InnoCare Pharma Financial Statements
InnoCare Pharma stakeholders use historical fundamental indicators, such as InnoCare Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although InnoCare Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in InnoCare Pharma's assets and liabilities are reflected in the revenues and expenses on InnoCare Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in InnoCare Pharma Limited. Please read more on our technical analysis and fundamental analysis pages.
InnoCare Pharma Limited, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. The company was incorporated in 2015 and is headquartered in Beijing, China. Innocare Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 531 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in InnoCare Pink Sheet
InnoCare Pharma financial ratios help investors to determine whether InnoCare Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in InnoCare with respect to the benefits of owning InnoCare Pharma security.